Kineta
85 articles with Kineta
-
Kineta to Present VISTA Biomarker Data at AACR Annual Meeting 2023
3/22/2023
Kineta, Inc., a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced that the company will present its VISTA clinical program at the American Association for Cancer Research Annual Meeting 2023, to be held onsite in Orlando, Florida on April 14-19, 2023.
-
Kineta to Present at the Oppenheimer 33rd Annual Healthcare Conference
3/8/2023
Kineta, Inc. announced today that Shawn Iadonato, Ph.D., Chief Executive Officer of Kineta, will present a corporate overview at the Oppenheimer 33rd Annual Healthcare Conference, a virtual event to be held on March 13-15, 2023.
-
Kineta to Host Key Opinion Leader Event on KVA12123: VISTA as an Immuno-Oncology Target
3/6/2023
Kineta, Inc. announced today it will host a virtual Key Opinion Leader (KOL) event on VISTA as an immuno-oncology target on Monday, March 20, 2023 at 10:00 AM ET.
-
Kineta Appoints Internationally-Renowned Clinical Immuno-oncology Experts to its Scientific Advisory Board
3/1/2023
Kineta, Inc. announced today the appointment of Myriam Chalabi, M.D. and Evan Ya-Wen Yu, M.D. to the company’s immuno-oncology focused Scientific Advisory Board (SAB).
-
Kineta Completes Reverse Merger with Yumanity Therapeutics
12/19/2022
Kineta, Inc., a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune resistance, announced the completion of its reverse merger with Yumanity Therapeutics, Inc.
-
Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with Kineta
12/5/2022
Yumanity Therapeutics, Inc. (“Yumanity” or the “Company”) (Nasdaq: YMTX) announced today that its Board of Directors has declared a special dividend in connection with the previously announced asset sale to Janssen Pharmaceutica NV.
-
Kineta to Present KVA12123 VISTA Blocking Immunotherapy Program at Antibody Engineering and Therapeutics Conference
12/1/2022
Kineta, Inc. announced that the Company will present at the Antibody Engineering and Therapeutics Conference, the Antibody Society’s Annual Meeting, to be held in-person in San Diego, CA from December 4-8, 2022.
-
Kineta to Participate in JMP Securities Hematology and Oncology Summit
11/29/2022
Kineta, Inc. announced today that the Company will present at the JMP Securities Hematology and Oncology Summit, a virtual investor event to be held from December 6-7, 2022.
-
Kineta Announces FDA Acceptance of Investigational New Drug (IND) Application for KVA12123 for the Treatment of Advanced Solid Tumors
11/15/2022
Kineta, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug application (IND) to evaluate its VISTA blocking immunotherapy, KVA12123 (formerly referred to as KVA12.1), as a potential treatment for patients with advanced solid tumors.
-
Kineta to Present Pre-clinical Data on VISTA and CD27 Programs at SITC 2022 Annual Meeting
10/27/2022
Kineta, Inc. announced that two abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer 37th Annual Meeting, to be held November 8-12, 2022 onsite in Boston, MA and online.
-
Kineta struck a collaboration deal with Merck to pair its anti-VISTA monoclonal antibody with Keytruda (pembrolizumab) as a potential treatment for advanced solid tumors.
-
Kineta Announces Clinical Collaboration with Merck to Evaluate KVA12123 in Combination with KEYTRUDA® (pembrolizumab) in Cancer Patients with Advanced Solid Tumors
10/17/2022
Kineta, Inc., a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology, announced that it has entered into a clinical trial collaboration and supply agreement with Merck.
-
Kineta to Present Anti-CD27 Agonist Preclinical Program at AACR Conference on Tumor Immunology and Immunotherapy
10/13/2022
Kineta, Inc. announced that it will present a poster on the Company’s anti-CD27 agonist antibody program at the American Association for Cancer Research Special Conference: Tumor Immunology and Immunotherapy, to be held on October 21-24, 2022 as an in-person event in Boston, Massachusetts.
-
Kineta Announces Participation in Upcoming October 2022 Investor Conferences
10/10/2022
Kineta, Inc., a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology, announced that the Company's management team will participate in the following investor conferences in October 2022.
-
Kineta Appoints Keith Baker as Chief Financial Officer
10/4/2022
Kineta, Inc., a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology, announced the appointment of Keith Baker as the Company's new Chief Financial Officer.
-
Kineta CSO Thierry Guillaudeux Invited to Participate at the 2nd Annual VISTA Virtual Symposium
9/14/2022
Kineta, Inc., a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology, announced that Thierry Guillaudeux, Ph.D., Kineta's Chief Scientific Officer, has been invited to present at the 2nd Annual VISTA Symposium.
-
Kineta Announces Participation in the H.C. Wainwright 24th Annual Global Healthcare Conference
9/12/2022
Kineta, Inc. announced today that it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference.
-
Kineta Announces Appointment of Thierry Guillaudeux, PhD to Chief Scientific Officer
6/28/2022
Kineta, Inc. ("Kineta" or the "Company"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today the appointment of Thierry Guillaudeux, PhD to Chief Scientific Officer of the Company.
-
Kineta Presents New Preclinical Data and Phase 1/2 Clinical Trial Design of KVA12.1 at the Tumor Myeloid-Directed Therapies Summit
6/17/2022
Kineta, Inc. announced that it presented the Phase 1/2 clinical trial design and new preclinical data supporting KVA12.1 as a potential treatment for cancer patients with advanced solid tumors at the Tumor Myeloid-Directed Therapies Summit held on June 14-16 in Boston, MA.
-
Aslan partners with Johns Hopkins and Duke, Editas joins forces with Immatics, Yumanity (soon to be Kineta, Inc.) teams with Janssen, Serotiny & Janssen Biotech and Ginkgo and Novo Nordisk.